Head of Regulatory Affairs at 2San: ‘A multibillion-dollar clash is brewing over the 340B drug discount program’

Head of Regulatory Affairs at 2San: ‘A multibillion-dollar clash is brewing over the 340B drug discount program’
Rachid Akiki, Head of Regulatory and Clinical Affairs at 2San — Provided photo
0Comments

Rachid Akiki, Head of Regulatory & Clinical Affairs at 2San, said the 340B drug discount program, originally meant to aid hospitals serving low-income populations, is now the center of a financial dispute over lost Medicaid rebates. The statement was made on X.

“A multibillion-dollar clash is brewing over the 340B drug discount program,” said Akiki, “Designed to help hospitals serve low-income patients, it’s now under fire. Drugmakers say it’s costing Medicaid $6.5B in lost rebates. Critics claim some hospitals are pocketing the savings instead of reinvesting in care.”

The 340B Drug Pricing Program was created by Congress in 1992 to help healthcare providers stretch scarce federal resources. It allows eligible hospitals and clinics to purchase outpatient drugs at discounted prices. According to the American Hospital Association, the program supports providers serving vulnerable and low-income populations.

The Medicaid and CHIP Payment and Access Commission reported in its March 2023 publication that drug manufacturers estimate the 340B program leads to $6.5 billion in lost Medicaid rebates. This is due to duplicate discounts when drugs are subject to both Medicaid rebates and 340B pricing. The issue has contributed to ongoing tensions between providers and drugmakers.

PhRMA reported that in New York, 113 hospitals participate in the 340B program, holding over 6,000 contracts with pharmacies nationwide. However, only 24% of these contract pharmacies are located in medically underserved areas, and 86% of participating hospitals provide below-average levels of charity care. This disparity has raised concerns about the program’s effectiveness in reaching its intended beneficiaries within the state.

Rachid Akiki is Head of Regulatory and Clinical Affairs at 2San and has led initiatives in healthcare strategy, innovation, and regulatory compliance. He previously served as Medical Director at XRWorkout and Chief Operating Officer at Book Doctors. He holds degrees from Harvard Medical School and Hult International Business School.



Related

Yankee Stadium

MLB Pipeline names top defensive prospects for each Major League club

MLB Pipeline has identified one top defensive prospect from each Major League Baseball team. The report highlights rookies poised to make an impact with their glove skills upon reaching the majors.

Citi Field

New York City FC reschedules match against Los Angeles Football Club to November 4

New York City FC has moved its upcoming match against Los Angeles Football Club to November due to LAFC’s tournament schedule. Tickets for the original date remain valid, and further updates may be provided if there are additional changes.

Randy Levine President

Gerrit Cole to begin Minor League rehab with Double-A Somerset on Friday

Gerrit Cole will start his Minor League rehab assignment with Double-A Somerset this Friday after recovering from Tommy John surgery last year. Yankees manager Aaron Boone confirmed that Anthony Volpe will also play with Somerset before moving up levels.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Empire State Today.